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Damage
Damaged cells release high-mobility group box 1
(HMGB1), activating inflammatory pathways via Toll-like
receptors (TLRs) 2 and 4 and advanced glycation end
products (RAGE). Nadatani et al (Am J Pathol 2012,
181:98–110) examined the role of HMGB1 in small intes-
tinal damage induced by nonsteroidal anti-inflammatory
drugs (NSAIDs), such as indomethacin. In wild-type
mice, recombinant human HMGB1 aggravated indo-
methacin-induced small intestinal damage and en-
hanced mRNA expression of inflammatory cytokines and
intracellular signaling molecules. Blocking HMGB1 with
neutralizing antibodies prevented these effects. TLR2-
and RAGE-knockout mice were highly sensitive to indo-
methacin, whereas TLR4-knockout mice exhibited less
severe intestinal damage, reduced TNF- mRNA expres-
sion, and no added effect from exogenous HMGB1.
Thus, HMGB1 appears to promote NSAID-induced small
intestinal damage via TLR4-dependent signaling.
Linking Osteoporosis and Bone Marrow
Failure after Pneumocystis Infection
Aside from susceptibility to opportunistic infections such as
Pneumocystis, unexplained complications in HIV and
AIDS patients include osteoporosis and bone marrow fail-
ure, respectively. Wilkison et al (Am J Pathol 2012, 181:
151–162) evaluated the potential connection between these
bone pathologies following Pneumocystis lung infection in
mice lacking both lymphocytes and type-I IFN receptor
(IFrag/). Pneumocystis infection accelerated osteoclasto-
genesis as bone marrow failure progressed in these mice,
consistent with induction of RANKL, TRAIL, and osteopro-
tegerin in the bone marrow of infected IFrag/ mice. Bi-
phosphonate treatment of IFrag/ mice prevented bone
loss and loss of hematopoietic precursor cells, which main-
tained activity in vitro; however, it did not prevent loss of
mature neutrophils. Thus, deregulation of the RANKL/OPG/
TRAIL axis—which is also deregulated in HIV individuals—
connects the bone loss and bone marrow phenotypes in
this model.
VLPs Protect Against MRSA
Priming the lung environment in anticipation of future lung
infections could provide an important novel therapy for
emerging infectious diseases. To test this, Rynda-Apple et
al (Am J Pathol 2012, 181:196–210) administered virus-like
particles (VLPs) to mice before, or immediately after, lethal
challenge with methicillin-resistant Staphylococcus aureus
(MRSA). This protocol provided complete recovery fromlung infection and near absolute clearance of bacteria
within 12 hours, reduced host response-induced lung tissue
damage, promoted recruitment and efficient bacterial clear-
ance, and protected macrophages from MRSA-induced
necrosis. Complete recovery occurred in VLP-dosed SCID
mice but not in wild-type mice depleted of either Ly6G or
CD11c cells. Early IL-13 production was also essential for
protection. These results provide important insights into host
anti-MRSA response mechanisms and suggest that VLPs
could be a viable means of enhancing these mechanisms.
Novel Axis Joins Stromal Cav-1 and mTOR
Signaling
To examine the effects of aging on mammary tumor growth,
Mercier et al (Am J Pathol 2012, 181:278–293) used Cav-1
knockout (KO) mice as a model of accelerated host aging.
Mammary tumor cells were orthotopically implanted into
age-matched young female Cav-1/ and Cav-1/ mice.
Tumors grown in Cav-1 KO mammary fat pads were signif-
icantly larger and showed increased stromal content, in-
cluding a proliferative stroma with hyperactivated mTOR
signaling. Systemic rapamycin treatment of mammary tu-
mors grown in a Cav-1 KO microenvironment significantly
inhibited tumor growth, decreased stromal content, and
reduced the levels of both vimentin (oxidative stress
marker) and phospho-S6 (aging marker) in Cav-1 KO can-
cer-associated fibroblasts. These results using Cav-1–defi-
cient mice as a pre-clinical model may have important
translational significance for the diagnosis and the thera-
peutic stratification of breast cancer patients.
Stem Cells Contribute to Vessel Graft Restenosis
Neointimal lesions commonly occur in artificial vessel grafts
used to treat occluded blood vessels. To clarify the cell
types involved, Tsai et al (Am J Pathol 2012, 181:362–373)
established a novel mouse model of restenosis by grafting
a decellularized vessel to the carotid artery. Grafts devel-
oped neointimal lesions that contained endothelial (ECs)
and smooth muscle cells (SMCs), monocytes, and stem/
progenitor cells. In stem cell medium, explanted cultures of
neointimal tissues displayed heterogeneous outgrowth, ex-
pressed c-kit, Sca-1, and CD34, and showed clonogenic
and multilineage differentiation capacities. Sca-1 cells
could differentiate in vitro into ECs and SMCs in response to
VEGF or PDGF-BB. In vivo local application of VEGF to
decellularized vessels directed EC differentiation. Conse-
quently, reduced SMC accumulation was observed, and
the rate of neointimal formation was markedly reduced.
Improved understanding of the cell types involved, together
with the novel model system, may yield effective tools in the
prevention or delay of restenosis.
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